Abstract
Next year, San Diego-based Ligand Pharmaceuticals is hoping to launch a third-generation selective estrogen receptor modulator (SERM) that it developed with Wyeth of Collegeville, Pennsylvania.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
